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BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes that mediate cell survival,
proliferation, and angiogenesis and is aberrantly activated in various types of malignancies, including renal cell carcinoma (RCC). We
examined whether it could be a novel therapeutic target for RCC by using the STAT3 inhibitor WP1066.
METHODS: The antitumour activities and related mechanisms of WP1066 were investigated in vitro on renal cancer cell lines and in vivo
on murine xenografts.
RESULTS: In Caki-1 and 786-O renal cancer cells, 5mM WP1066 prevented the phosphorylation of STAT3, and 2.5mM WP1066
significantly (Po0.01) inhibited cell survival and proliferation. WP1066 suppressed the expression of Bcl-2, induced apoptosis, and
inhibited the basal and hypoxia-induced expression of HIF1a and HIF2a, as well as vascular endothelial growth factor secretion into
cell culture medium. Human umbilical vascular endothelial cells cocultured with media from WP1066-treated cells showed
significantly reduced tubulogenesis (Po0.05). Systemic oral administration of WP1066 to mice for 19 days significantly inhibited the
growth of Caki-1 xenograft tumours (Po0.05), and pathological analysis of xenografts of WP1066-treated mice showed decreased
immunostaining of phosphorylated STAT3 and reduced length of CD34-positive vessels (Po0.05).
CONCLUSIONS: Our results suggest that using WP1066 to inhibit the STAT3 signalling pathway could be a novel therapeutic strategy
against RCC.
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Signal transducer and activator of transcription (STAT) proteins
have been shown to have important roles in cytokine and growth
factor signalling pathways (Schindler and Darnell, 1995). These
proteins are latent in cytoplasm and become activated through
tyrosine phosphorylation, which typically occurs through cyto-
kine-receptor-associated kinases, Janus kinases, or growth factor
receptor tyrosine kinases (Schindler and Darnell, 1995). The
activated STAT proteins then translocate to the nucleus and
activate the transcription of target genes (Darnell, 1997). One of
the STAT proteins, STAT3, was originally identified as an acute
phase response factor activated by the interleukin-6 (IL-6) family
of cytokines (Akira et al, 1994). Further studies have shown STAT3
to be activated in response to a variety of other cytokines and
growth factors, including epidermal growth factor, platelet-derived
growth factor, and transforming growth factor-a, as well as by
oncogenic proteins such as Src and Ras (Schindler and Darnell,
1995; Darnell, 1997; Aggarwal et al, 2009). STAT3 has also been
reported to regulate the transcription of key components of cell-
cycle control and to modulate the activity of proteins regulating
apoptosis (Zushi et al, 1998; Catlett-Falcone et al, 1999; Amin et al,
2004).
Signal transducer and activator of transcription-3 has been
reported to be constitutively activated in various types of malignant
tumours, and increased STAT3 activation has been recognised as an
indicator of poor prognosis (Huang, 2007; Al Zaid Siddiquee and
Turkson, 2008; Aggarwal et al, 2009). Constitutively activated
STAT3 signalling in tumours has been shown to promote cell-cycle
progression and prevent apoptosis by modulating cell cycle-
associated and apoptosis-associated proteins such as cyclin D1
and Bcl-2; this is a possible mechanism of resistance to conventional
chemotherapy and radiotherapy (Huang, 2007; Al Zaid Siddiquee
and Turkson, 2008; Aggarwal et al, 2009). The activation of STAT3
has also been shown to upregulate vascular endothelial growth
factor (VEGF) expression and promote tumour angiogenesis (Niu
et al, 2002; Wei et al, 2003). STAT3 has therefore been considered as
a potential therapeutic target for cancer treatment.
Renal cell carcinoma (RCC) is the most common malignant
tumour of the adult kidney and accounts for approximately 3% of
all adult cancer cases (Bilim et al, 2009; Thompson Coon et al,
2009). Unlike many other malignancies, RCC is generally resistant
to conventional therapy (Bilim et al, 2009; Thompson Coon et al,
2009). Having previously reported a high frequency of increased
STAT3 activation in RCC, especially in metastatic disease
(Horiguchi et al, 2002b), we thought that STAT3 could be a novel
therapeutic target for RCC and, in this study, examined whether
the STAT3 inhibitor WP1066 shows antitumour activity against
RCC in vitro and in vivo.
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Cell culture and reagents
Human renal cancer cell lines Caki-1 and 786-O (American Tissue
Culture Collection, Manassas, VA, USA) were used in this study,
and WP1066 (Calbiochem, La Jolla, CA, USA) was dissolved in
DMSO at 50mM. The antibodies used in this study were antibodies
against phospho-STAT3 (p-STAT3, Cell Signaling Technology Inc.,
Beverly, MA, USA), STAT3 (Cell Signaling Technology Inc),
phospho-extracellular-activated protein kinase (ERK) (p-ERK, Cell
Signaling Technology Inc.), ERK (Cell Signaling Technology Inc.),
cleaved poly(ADP-ribose) polymerase (PARP) (Cell Signaling
Technology Inc.), Bcl-xl (Cell Signaling Technology Inc.), Bcl-2
(Cell Signaling Technology Inc.), HIF1a (BD Transduction
Laboratories, Lexington, KY, USA), HIF2a (Novus Biologicals,
Littleton, CO, USA), and b-actin (Chemicon International Inc.,
Temecula, CA, USA). Horseradish-peroxidase-conjugated second-
ary antibodies and an enhanced chemiluminescence system were
obtained from Amersham Pharm Biotech (Piscataway, NJ, USA).
Cell viability assays and cell counts
Cell viability was assessed by the MTS assay using the Cell Titer96
AQueous Non-Radioactive Cell Proliferation Assay (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.
Briefly, cells were incubated overnight in 96-well plates (3 10
3
cells/well) and then treated for 48h with the indicated concentra-
tion of WP1066 (in DMSO) or with the corresponding amount of
DMSO. Two hours after adding MTS, plates were read in a
microplate autoreader at a wavelength of 490nm. The results were
expressed as the mean optical density of the six-well set for each
group, and the plates were measured twice with similar results. For
cell counts, after being incubated overnight in six-well plates
(2 10
4 cells/well in triplicate), cells were treated with 2.5 or 5mM
WP1066 or with the corresponding amount of DMSO. Total cell
numbers in three independent wells in each group were counted at
the indicated time by using a hemocytometer, and the mean value
of four fields was recorded.
Determination of apoptosis
Apoptotic cells were assessed by double staining with FITC-
conjugated annexin-V and propidium iodide. This staining was
carried out using the Annexin V Apoptosis Detection Kit (Santa-
Cruz Biotechnology Inc., Santa Cruz, CA, USA). To observe
nuclear morphological changes with a fluorescence microscope, we
fixed cells with 4% paraformaldehyde for 30min at room
temperature and stained them with 1mM Hoechst 33258 (Sigma,
St Louis, MO, USA).
Western blot analysis
Cells that had been treated with 2.5 or 5mM WP1066 or the
corresponding amount of DMSO for 24h were lysed in RIPA buffer
(10mM Tris-HCl, 150mM NaCl, 1% Triton X-100, 5mM EDTA, 1%
sodium deoxycholate, 0.1% SDS, 1.2% aprotinin, 5mM leupeptin,
4mM antipain, 1mM phenylmethylsulphonyl fluoride, and 0.1mM
Na3VO4) before equal amounts of proteins were subjected to
western blotting as described previously (Horiguchi et al, 2004).
Hypoxia treatment and determination of VEGF production
Cells were plated at 1 10
4 cells/well in six-well plates in RPMI
1640 containing 10% FCS, cultured for 24h and then washed with
serum-free medium and cultured for an additional 24h in 1ml of
serum-free medium in the presence or absence of 5mM WP1066
under normoxic or hypoxic (1% O2) conditions. The medium was
collected and centrifuged. The levels of VEGF in the supernatants
were analysed using a Quantikine Human VEGF Immunoassay kit
(R&D Systems, Minneapolis, MN, USA) and were normalised to
the total protein content measured by the Bradford assay.
Assessment of in vitro angiogenesis
In vitro angiogenesis was assessed according to the formation of
capillary-like structures of human umbilical vascular endothelial
cells (HUVECs) cocultured with human diploid fibroblasts as
described previously (Horiguchi et al, 2004). The experimental
procedure followed the instructions provided with the angiogen-
esis kit we used (Kurabo, Tokyo, Japan). Briefly, HUVECs were
incubated in the conditioned medium, which was replaced at days
4, 7, and 9. On day 11, cells were fixed and stained using an anti-
human CD31 antibody (Kurabo) according to the provided
instructions. The formation of the capillary network was observed
with a microscope at  40 magnification. The total length of the
tube-like structures in five randomly chosen microscope fields was
measured by ImageJ (Bethesda, MD, USA) software.
Xenograft model
Caki-1 cells (3 10
6 cells per 100ml) were inoculated subcuta-
neously into the flanks of nude mice. When the average tumour
diameter reached 5mm, the mice were randomly divided into two
groups (eight each), one of which was treated with WP1066
(40mgkg
 1) injected by oral gavage in a mixture of 20 parts
DMSO to 80 parts polyethylene glycol 300 (Sigma-Aldrich, Tokyo,
Japan) once per day (5 days on and 2 days off) as described
elsewhere (Kong et al, 2008), and the other of which was treated
with vehicle. The size of each tumour was monitored every 3 or 4
days until the 19th day after the first treatment. Tumour volume
(mm
3) was estimated using the following formula:
volume¼width
2 length 0.52. Animal experimentation proce-
dures were reviewed and approved by the National Defense
Medical College’s Animal Care and Use Committee.
Immunohistochemistry
Immunohistochemistry was performed as described previously
(Horiguchi et al, 2002b). Briefly, formalin-fixed, paraffin-em-
bedded tumour sections (4mm) were deparaffinised in xylene and
rehydrated through graded ethanols. The slides were placed in
DAKO Target Retrieval Solution High pH (Dako Corporation,
Carpinteria, CA, USA) and heated for 40min for antigen retrieval.
Endogenous peroxidase activity was quenched with Dako Per-
oxidase Blocking Reagent (Dako Corporation) for 10min. The
sections were incubated in 10% normal goat serum in PBS for
60min at room temperature. After the sections were incubated
overnight at 41C with anti-phospho-STAT3 antibody, anti-STAT3
antibody, or anti-CD34 antibody (clone MEC14.7, Hycult
Biotechnology, Uden, The Netherlands) at 1:50 dilution in PBS,
the slides were stained using a Simple Stain Max PO kit (Nichirei
Corporation, Tokyo, Japan) according to the manufacturer’s
instructions. Reaction products were visualised by immersing
slides in DAB for 5min. The vascularity in each tumour specimen
was estimated using an anti-CD34 antibody. Three areas of most
intense vascularisation were selected under a light microscope with
a 100-fold magnification. The total length of the tube-like
structures was measured by ImageJ software, and for each section,
the mean length in the selected areas was recorded.
Statistical analysis
The statistical significance of differences was evaluated by
unpaired t-testing, and P-values less than 0.05 were considered
to indicate significance.
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WP1066 inactivates STAT3 and suppresses renal cancer
cell viability and proliferation
We first tested whether WP1066 inactivated STAT3 in Caki-1
and 786-O renal cancer cells. STAT3 is latent in the cytoplasm and
its activation is accompanied by tyrosine phosphorylation at
Tyr705, which induces dimerisation, nuclear translocation, and
binding to DNA (Schindler and Darnell, 1995). Cell lysates were
subjected to western blotting after Caki-1 and 786-O cells were
incubated for 24h with 2.5 or 5mM WP1066, concentrations known
to suppress STAT3 activity (Ferrajoli et al, 2007; Iwamaru et al,
2007; Kong et al, 2008; Verstovsek et al, 2008). WP1066 inhibited
phosphorylation of STAT3 in a dose-dependent manner
(Figure 1A). We also examined its effect on another key
component of signal transduction pathways and found that in
both cell lines it stimulated the phosphorylation of ERK
(Figure 1A).
We next examined the ways in which the viability and
proliferation of renal cancer cells were affected when STAT3
activity was inhibited by WP1066. We treated Caki-1 and 786-O
cells with the indicated concentration of WP1066 for 48h and
examined cell viability by MTS assay. The viability of both cell
lines was significantly decreased in a dose-dependent manner
(Po0.01) (Figure 1B). In triplicate observations made 1 and 2 days
after Caki-1 and 786-O cells were treated with 5mM WP1066, it
was found that the total number of WP1066-treated cells was
significantly (Po0.01) less than the number of DMSO-treated cells
(Figure 1C).
Caki-1
p-STAT3
WP1066 (M) 0
STAT3
p-ERK
ERK
Caki-1 786-O
R
e
l
a
t
i
v
e
 
v
a
l
u
e
R
e
l
a
t
i
v
e
 
v
a
l
u
e
##
#
#
#
#
# #
1
1.2
0.2
0.4
0.6
0.8
0
0 1 2.5 5 10
WP1066 (M) WP1066 (M)
1
1.2
0.2
0.4
0.6
0.8
0
0 1 2.5 5 10
Caki-1 786-O
C
e
l
l
 
n
u
m
b
e
r
 
(
×
 
1
0
4
)
C
e
l
l
 
n
u
m
b
e
r
 
(
×
 
1
0
4
)
0 M
2.5 M
5 M
##
0 M
2.5 M
5 M
8
3
4
5
6
7
0
1
2
02 4 4 8
##
Time (h)
3.5
4
1.5
2
2.5
3
0
0.5
1
02 4 4 8
##
##
Time (h)
5 2.5 5 2.5 0
786-O
Figure 1 WP1066 inactivates STAT3 and suppresses the growth and viability of renal cancer cells. (A) WP1066 inhibited STAT3 phosphorylation, while
stimulating ERK, in Caki-1 and 786-O cells. Caki-1 and 786-O cells were treated with the indicated concentration of WP1066 for 24h and cell lysates were
subjected to western blotting. (B) MTS-assay-determined viability of Caki-1 and 786-O cells treated with the indicated concentration of WP1066 for 24h.
Note the significantly lower viability of WP1066-treated cells (
#, Po0.01;
##, Po0.05). The results are expressed as the mean ± s.e. of the three sets for
each group. (C) Proliferation of Caki-1 and 786-O cells in six-well plates treated with the indicated concentration of WP1066. Total cell numbers were
counted at 24 and 48h. Note the significantly reduced proliferation of WP1066-treated cells (
##, Po0.01). The results are expressed as the mean ± s.e. of
the three sets for each group.
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Activated STAT3 has been shown to inhibit apoptosis by
upregulating apoptotic regulatory proteins such as antiapoptotic
proteins Bcl-2, Bcl-xl, and Mcl-1 (Zushi et al, 1998; Catlett-Falcone
et al, 1999; Amin et al, 2004). To examine whether WP1066 would
induce apoptosis in renal cancer cells, Caki-1 and 786-O cells
incubated for 24h with 2.5 or 5mM WP1066 were double stained
with annexin-V and propidium iodide and were analysed by flow
cytometry. The percentage of the population that was annexin
positive and propidium iodide negative, which are apoptotic cells,
was greater in cells treated with WP1066 than in control cells
(Figure 2A). The nuclei of WP1066-treated cells seemed lobated
and severely fragmented and contained highly condensed chro-
matin (Figure 2B), which are findings typical of apoptosis. To
confirm apoptosis, we examined cells for the presence of PARP
cleavage after treatment with WP1066. Cleaved PARP was evident
in both Caki-1 and 786-O cells treated with WP1066 for 24h
(Figure 2C). The expression of Bcl-2 in both cell lines decreased
24h after treatment with WP1066, whereas that of Bcl-xl or Mcl-1
did not (Figure 2C).
WP1066 suppresses HIF1a and HIF2a expression and
VEGF production
Vascular endothelial growth factor is one of the most potent
proangiogenic factors, and renal cancer cell lines, including Caki-1
and 786-O cells, have been shown to produce VEGF (Shinojima
et al, 2007). Recent studies have identified that STAT3 is a direct
transcription activator of the VEGF gene and that activation of
STAT3 leads to tumour angiogenesis (Jung et al, 2005; Xu et al,
2005). We therefore examined whether WP1066 could suppress
basal and hypoxia-stimulated production of VEGF. We incubated
Caki-1 and 786-O cells with 5mM WP1066 under normoxic or
hypoxic (1% O2) conditions for 24h and measured VEGF levels in
the supernatants. Caki-1 has the wild-type von-Hippel-Lindau
(VHL) gene and expresses both HIF1a and HIF2a, whereas 786-O
has a mutant VHL gene and expresses HIF2a but not HIF1a
(Shinojima et al, 2007). It has been reported that HIF1a has a
predominant role in VEGF production in Caki-1 cells but that
HIF2a regulates VEGF production in 786-O cells (Shinojima et al,
2007). We found the VEGF level in Caki-1 cells incubated under
hypoxic conditions to be significantly (60%) higher than that in
Caki-1 cells incubated under normoxic conditions (Po0.05,
Figure 3A). The VEGF level in 786-O cells, on the other hand,
was not increased under hypoxic conditions (Figure 3A). WP1066
significantly (Po0.01) suppressed basal and hypoxia-stimulated
VEGF production in both Caki-1 and 786-O cells (Figure 3A). A
recent study has demonstrated that STAT3 increased the levels of
HIF1a in Caki-1 cells by blocking its degradation and accelerating
its de novo synthesis (Jung et al, 2005). We further examined
whether WP1066 modulates HIF1a or HIF2a expression. In Caki-1
cells, hypoxic incubation increased the expression of HIF1a,
HIF2a, and phosphorylated STAT3, and these increases were
suppressed by WP1066 (Figure 3B). In 786-O cells, on the other
hand, levels of HIF2a and phosphorylated STAT3 expression were
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Figure 2 WP1066 downregulates antiapoptotic protein Bcl-2 and induces apoptosis in renal cancer cells. (A) Annexin V staining for apoptosis assay in
Caki-1 and 786-O cells incubated for 24h with the indicated concentration of WP1066. The percentages of annexin-V-positive- and propidium-iodide-
negative (early apoptosis) fractions are indicated. (B) Nuclear morphologies observed by fluorescence microscopy after staining with Hoechst 33258 after
Caki-1 and 786-O cells had been incubated for 24h with the indicated concentration of WP1066. Note the fragmented and condensed nuclei characteristic
of apoptosis. (C) Western blot analysis of apoptosis-related proteins. Cells were treated with the indicated concentration of WP1066 for 24h and subjected
to western blotting. Actin was used as an internal control.
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WP1066 (Figure 3B).
WP1066 inhibits in vitro angiogenesis
We next examined the effect of WP1066 on in vitro angiogenesis
by using an HUVEC tubulogenesis assay. We incubated Caki-1 and
786-O cells with or without 5mM WP1066 under normoxic or
hypoxic conditions for 24h and collected the supernatants. These
conditioned media were applied to HUVEC plates cultured in
matrigel and the length of the tubular structures was measured.
The tubular structures in HUVECs cultured in conditioned
media obtained when Caki-1 cells had been incubated under
hypoxic conditions were significantly (Po0.05) longer than
those in HUVECs cultured in conditioned media obtained when
Caki-1 cells had been incubated under normoxic conditions
(Figures 4A and B). On the other hand, hypoxic incubation had
no effect on the length of tubular structures in HUVECs cultured in
conditioned media obtained from 786-O cells (Figures 4A and B).
The length of tubular structures in HUVEC cultured in condi-
tioned media obtained from both Caki-1 and 786-O cells treated
with WP1066 was significantly (Po0.01) shorter than that in
HUVECs cultured in conditioned media obtained from cells not
treated with WP1066 (Figures 4A and B).
WP1066 inhibits tumour growth in the murine xenograft
model of Caki-1 cells
As WP1066 inhibited the growth of renal cancer cells and
angiogenesis in vitro, we tested the efficacy of WP1066 against
renal cancer xenografts. WP1066 administrated orally is more
efficacious and less toxic than WP1066 injected intraperitonealy or
intravenously (Kong et al, 2008). When established Caki-1
xenografts were treated, 5 days on and 2 days off for a total of
19 days, with WP1066 (40mgkg
 1 orally) or only the vehicle
(DMSO and polyethylene glycol 300), the mean volume of tumours
treated with WP1066 (304.7±50.0mm
3) was significantly
(Po0.05) smaller than that of tumours treated with only the
vehicle (788.9±239.7mm
3, Figures 5A and B).
WP1066 inactivates STAT3 in vivo and inhibits tumour
angiogenesis
We next performed immunohistochemical analysis of Caki-1
xenograft tumours to examine whether WP1066 inhibited its
growth by inactivating STAT3. STAT3 is latent in the cytoplasm
and its activation is accompanied by tyrosine phosphorylation,
which induces dimerisation, nuclear translocation, and binding to
DNA (Schindler and Darnell, 1995). Consistent with the current
understanding of STAT3 signalling pathways, predominant
nuclear immunostaining of phosphorylated STAT3 was observed
in the vehicle-treated control tumours (Figure 5C, upper left). In
WP1066-treated tumours, on the other hand, there was little
p-STAT3 immunostaining (Figure 5C, upper right). Similar total
STAT3 immunostaining was observed in both vehicle-treated and
WP1066-treated tumours, suggesting that WP1066 inhibited
phosphorylation of STAT3 without modulating STAT3 expression
(Figure 5C, middle row). To examine whether WP1066 inhibits
tumour angiogenesis, we immunostained xenograft tumours with
CD34 and measured the length of CD34-positive vessels in each
tumour (Figure 5C, lower row). The mean total length of CD34-
positive vessels in WP1066-treated tumours was significantly
(Po0.05) shorter than that in vehicle-treated control tumours
(Figure 5D).
DISCUSSION
In this study, we showed that in Caki-1 and 786-O renal cancer
cells, STAT3 inhibitor WP1066 inactivated the STAT3 signalling
pathway and induced apoptosis, accompanied by reduced Bcl-2
expression. WP1066 downregulated HIF1a and HIF2a expression
under both normoxic and hypoxic conditions, resulting in reduced
VEGF production and in vitro angiogenesis. Moreover, oral
administration of WP1066 significantly suppressed tumour
angiogenesis and inhibited the growth of xenograft tumours
generated from Caki-1 cells. Our results suggest that inhibiting the
STAT3 signalling pathway by using WP1066 could be a novel
therapeutic strategy against RCC.
Activated STAT3 fosters tumourigenesis by preventing apopto-
sis, enhancing proliferation, angiogenesis, invasiveness, and
immune evasion (Huang, 2007; Al Zaid Siddiquee and Turkson,
2008; Aggarwal et al, 2009). In various types of malignant tumours,
including leukaemia and cancers of the breast, head and neck,
melanoma, prostate, pancreas, and colon, activation of STAT3 is
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saberrantly increased (Huang, 2007; Al Zaid Siddiquee and
Turkson, 2008; Aggarwal et al, 2009). We have previously
identified a high frequency (50%) of increased STAT3 activation
in RCC by immunohistochemical analysis (Horiguchi et al, 2002b).
The STAT3 is also known to be involved in regulating cancer
metastasis, and activation of STAT3 correlates with lymph node
and distant metastasis (Huang, 2007). High levels of STAT3
activation are also significantly associated with the presence of
metastasis and poor survival rate in RCC (Horiguchi et al, 2002b).
These studies showed that inhibitors of the STAT3 signalling
pathway have enormous potential in the treatment of cancer and
drove us to examine its efficacy against RCC.
Several strategies for developing effective inhibitors of STAT3
have been pursued. One small-molecule STAT3 inhibitor, AG490,
was originally selected from a group of tyrphostins screened for
their ability to block Jak2 activity and has been shown to inhibit
growth and induce apoptosis in some types of cancer cells,
including renal cancer cells (Meydan et al, 1996; Horiguchi et al,
2002a). However, AG490 can inhibit STAT3 only at high
concentrations (IC50 value¼50–100mM) and therefore has not
been shown to have an in vivo antitumour effect in animal models
(Meydan et al, 1996; Horiguchi et al, 2002a). Priebe and his
colleagues synthesised WP1066 by modifying the structure of
AG490, and WP1066 has been shown to inhibit STAT3 activity and
to have a potent antitumour effect on malignant glioma cells, both
in vitro and in vivo (Iwamaru et al, 2007). Marked antitumour
activity of WP1066 has also been shown against head and neck
carcinoma, pancreatic cancer, bladder cancer, B-cell non-Hodgkin’s
lymphoma, and chronic myelogenous leukaemia (Ferrajoli et al,
2007; Kong et al, 2008; Verstovsek et al, 2008). We previously
showed that the proliferation of Caki-1 cells is inhibited by high
concentrations of AG490 (IC50 value¼30.0mM) (Horiguchi et al,
2002a), and here we showed that the proliferation of Caki-1 cells is
significantly inhibited by WP1066 at a concentration as low as
2.5mM. Moreover, oral administration of WP1066 significantly
inhibited the growth of Caki-1 xenografts, and pathological
examination showed reduced STAT3 activation in WP1066-treated
xenografts. Thus, in accordance with previous studies (Ferrajoli
et al, 2007; Hussain et al, 2007; Iwamaru et al, 2007; Kong et al,
2008; Verstovsek et al, 2008), WP1066 is a potent STAT3 inhibitor
both in vitro and in vivo.
In addition to the inhibitory effect on STAT3 activation,
WP1066 has also been shown to inhibit Jak2/STAT3 activation
induced by cytokines and STAT5 (Ferrajoli et al, 2007; Iwamaru
et al, 2007; Kong et al, 2008). In our preliminary experiments, we
examined the activation of Jak2 and STAT5 in Caki-1 and 786-O
cells cultured in media with 10% FBS and did not detect activated
Jak2 or activated STAT5 in either cell line (data not shown).
Moreover, treatment with WP1066 had no effect on their activation
status. On the other hand, treatment of Caki-1 and 786-O cells with
WP1066 simultaneously decreased STAT3 activation and increased
ERK activation. The constitutive activation of ERK has been shown
to occur frequently in RCC, especially in clear cell carcinoma, and
the levels of activated ERK increased with increasing tumour size
and tumour stage (Oka et al, 1995; Campbell et al, 2009).
Moreover, increased activation of ERK is an independent indicator
of poor prognosis in patients with RCC (Campbell et al, 2009). In
our preliminary study, we further examined activated ERK
expression immunohistochemically in xenograft tumours from
mice treated with WP1066 and mice treated with vehicle. The
staining intensity in tumours treated with WP1066 was much
stronger than that in control tumours, which was the inverse of
what was observed with p-STAT3 immunostaining (data not
shown). Because ERK activation has been shown to be essential for
mitogenic signals and to promote cancer proliferation and
metastasis in various types of cancer including RCC (Campbell
et al, 2009), WP1066-induced activation of ERK might compromise
its antitumour activity.
Activated STAT3 has been shown to protect tumour cells from
apoptosis by regulating genes encoding antiapoptosis-associated
proteins, such as Bcl-2, Bcl-xl, and Mcl-1 (Zushi et al, 1998; Catlett-
Falcone et al, 1999; Amin et al, 2004). Bcl-2 is frequently expressed
in RCC, and a Bcl-2 overexpression may explain the resistance of
RCC to conventional chemotherapy and radiotherapy (Tomita
et al, 1996; Huang et al, 1999). We previously showed that AG490
inhibited STAT3 and induced apoptosis accompanied by the
downregulation of Bcl-2 in renal cancer ACHN cells (Horiguchi
et al, 2002a). In line with our previous study, we herein showed
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Figure 4 WP1066 inhibited in vitro angiogenesis. The HUVECs were incubated in a cell-conditioned medium with 5mM WP1066 under normoxic (norm)
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sthat WP1066 downregulated Bcl-2 expression effectively and
induced apoptosis in both Caki-1 and 786-O cells.
Recent studies have identified STAT3 as a direct transcription
activator of the VEGF gene and showed that activation of STAT3
leads to tumour angiogenesis in vivo (Niu et al, 2002; Wei et al,
2003). Mutations of VHL tumour suppressor protein are found in
most clear-cell RCC, and loss of VHL protein function leads to
elevated levels of HIFa and consequent overexpression of VEGF
(Motzer et al, 2006). Recent studies demonstrated that STAT3 has
a pivotal role in the regulation of HIF1a protein expression and
stability and enhances HIF1a-mediated expression of VEGF by
interacting with HIF1a (Jung et al, 2005; Xu et al, 2005). Here, we
showed that incubating Caki-1 cells under hypoxic conditions
activated STAT3, upregulated HIF1a expression, and enhanced
VEGF production, and that all of these effects were inhibited by
treatment with 5mM WP1066. Jung et al previously showed that
AG490 inhibited hypoxia-induced activation of STAT3, as well as
HIF1a expression and VEGF production, but this inhibition
required a much higher concentration (30mM) (Jung et al, 2005).
On the other hand, VEGF production is not stimulated by hypoxia
in VHL-mutated 786-O cells (Shinojima et al, 2007). Accordingly,
we found hypoxic conditions to have no effect on VEGF
production or on STAT3 phosphorylation levels in 786-O cells,
both of which were inhibited by treatment with WP1066.
Interestingly, WP1066 markedly inhibited the expression of HIF2a,
which has a crucial role in VEGF transcriptional regulation in
786-O cells (Shinojima et al, 2007). Our results suggest that not
only HIF1a but also HIF2a might be regulated by STAT3. The
HUVECs that were cocultured with the supernatants from Caki-1
and 786-O cells incubated with WP1066 showed reduced tubular
formation, and our pathological assessment of the xenograft
tumours showed that WP1066 reduced STAT3 activation and
the length of CD34-positive microvessels. Our data suggest that
WP1066 suppresses VEGF production and tumour angiogenesis
under both normoxic and hypoxic conditions regardless of the
VHL gene mutation status. To our knowledge, this report is the
first to show that WP1066 inhibits tumour angiogenesis.
Surgical resection remains the mainstay of therapy for localised
RCC, and metastatic RCC is highly refractory to conventional
radiation therapy and chemotherapy (Bilim et al, 2009; Thompson
Coon et al, 2009). The recent discovery and clinical development
of some targeted agents have expanded treatment options in
metastatic RCC (Escudier et al, 2009; Motzer et al, 2009), but
complete response is rare and most patients eventually fail
the treatment with targeted agents. The management of advanced
RCC therefore remains a significant challenge to clinicians. Our
study suggests that WP1066 is potentially useful for treating
metastatic RCC.
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